Sanofi and Regeneron Launch Phase 3 Study on Itepekimab for Chronic Rhinosinusitis
A Phase 3 extension study has been initiated to assess the long-term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps.